Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
Exploration of Treatment-Response Biomarkers in Breast Cancer Based on Integrated Liquid-Biopsy Multimodal Omics Features
This single-center cohort study integrates humoral immune response profiling (Phage ImmunoPrecipitation Sequencing, PhIP-seq) with circulating cell-free DNA (cfDNA) genomic and epigenomic features, exosome transcriptomics, and plasma metabolomics to discover and validate liquid-biopsy biomarkers of treatment response in breast cancer.
The study comprises four cohorts: (1) a retrospective pan-cancer cohort of approximately 1,000 patients with solid malignant tumor, using archived residual serum/plasma to construct a pan-cancer antigen repertoire and cfDNA mutational/methylation atlas, with priority given to patients who had available Whole Exome Sequencing (WES) data; (2) a prospective cohort of 800 women with non-metastatic (M0) breast cancer receiving standard neoadjuvant chemotherapy (NAC); (3) a prospective cohort of 100 women with metastatic (M1) breast cancer receiving standard systemic therapy; and (4) a control group of 100 individuals, including patients with benign breast disease (breast fibroadenoma) and healthy volunteers.
The primary objective is to identify biomarkers-autoantibody repertoires, cfDNA mutation clearance, methylation reprogramming, exosome transcripts, and metabolic signatures-associated with pathological complete response (pCR) to NAC, and to develop predictive models where feasible.
Panoramica dello studio
Stato
Descrizione dettagliata
Peripheral blood (20 mL) is collected at protocol-defined time points. Serum/Plasma autoantibody repertoires are profiled by PhIP-seq(phage-display immunoprecipitation sequencing); cfDNA methylation is measured by bisulfite-free methylome profiling; exosome RNA is profiled by strand-specific RNA sequencing; and untargeted plasma metabolomics is performed by liquid chromatography-tandem mass spectrometry. The study endpoints include clinical response and pathological complete response after NAC, together with survival follow-up. The study is conducted in accordance with the Declaration of Helsinki and Chinese regulations for investigator-initiated research, and has been approved by the institutional ethics committee.
Ambispective - a retrospective pan-cancer cohort (archived samples, 2020 Jan - 2026. Sep) combined with prospective breast cancer cohorts (enrollment 2026. Oct -2029)
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Kai Chen Principal Investigator, MD, PhD
- Numero di telefono: +86 0660-3863000
- Email: chenkai23@mail.sysu.edu.cn
Luoghi di studio
-
-
Guangdong
-
Shanwei, Guangdong, Cina, 516601
- Reclutamento
- Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contatto:
- Kai Chen Principal Investigator, MD, PhD
- Numero di telefono: +86 0660-3863000
- Email: chenkai23@mail.sysu.edu.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Study participants will be selected from three main sources: (1) healthy female volunteers recruited for this study; (2) patients receiving clinical treatment at our institution; and (3) patients undergoing relevant diagnostic or clinical examinations at our institution.
Descrizione
Inclusion Criteria:
Retrospective pan-cancer cohort:
- Aged 18 to 80 years;
- Both genders
- Clinically and histopathologically confirmed diagnosis of solid malignant tumors, including but not limited to non-small cell lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, or breast cancer.
- Complete clinical data available, including definitive TNM stage and established treatment plan;
- Archived peripheral blood samples (serum/plasma) collected during routine clinical care.
Prospective neoadjuvant chemotherapy (NAC) breast cancer cohort:
- Female, aged 18 to 80 years (inclusive);
- Clinically and pathologically confirmed non-metastatic (M0) breast cancer;
- Planned standard NAC at the study site, with complete pre-treatment ER, PR, and HER2 immunohistochemistry results available;
- Voluntary participation with signed written informed consent.
Prospective metastatic breast cancer cohort:
- Female, aged 18 to 80 years (inclusive);
- Clinically and pathologically confirmed metastatic (M1) breast cancer;
- Planned standard systemic therapy at the study site, with complete ER, PR, and HER2 immunohistochemistry results available;
- Voluntary participation with signed written informed consent.
Benign/Healthy control group:
- Healthy female volunteers, or female patients with breast fibroadenoma undergoing minimally invasive biopsy during the same period;
- Voluntary participation with signed written informed consent.
Exclusion Criteria:
For prospective breast cancer cohorts:
- History of mastitis, or systemic rheumatic/autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis);
- Acute or chronic infectious diseases within the past 6 months (e.g., pneumonia, pulmonary tuberculosis, active hepatitis);
- Long-term use of glucocorticoids, immunosuppressants, biologic agents, or psychotropic medications (short-term or as-needed use excepted);
- Inability or refusal to provide informed consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: OTHER
Coorti e interventi
Gruppo / Coorte |
|---|
|
Retrospective Pan-Cancer Cohort
Patients aged 18-80 years with histologically confirmed solid malignant tumors( e.g. non-small cell lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, or breast cancer), diagnosed at the study site between January 2020 and Sep 2026, with complete clinical data (TNM stage and treatment plan) and archived residual serum/plasma samples. Approximately 1,000 cases. |
|
Prospective Neoadjuvant Chemotherapy (NAC) Breast Cancer Cohort
Women aged 18-80 years with clinically and pathologically confirmed non-metastatic (M0) breast cancer who plan to receive standard NAC at the study site, with complete pre-treatment ER, PR, and HER2 immunohistochemistry results. Planned enrollment: 800. Peripheral blood (20 mL) is collected before, during, and after NAC (pre-surgery), in addition to routine clinical data. |
|
Prospective Benign/Control Group (Breast Fibroadenoma or Healthy Volunteers)
Patients with breast fibroadenoma undergoing minimally invasive biopsy during the same period, serving as benign controls to calibrate background signals of circulating antigens and liquid-biopsy analytes. Healthy female volunteers will also be enrolled. Planned enrollment: 100. |
|
Prospective Metastatic Breast Cancer Cohort
Women aged 18-80 years with clinically and pathologically confirmed metastatic (M1) breast cancer who plan to receive standard systemic therapy at the study site, with complete ER, PR, and HER2 immunohistochemistry results.Planned enrollment: 100. Serial peripheral blood samples are collected before, during, and after treatment. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pathological Complete Response (pCR) Rate
Lasso di tempo: At definitive surgery after completion of NAC (approximately 4-6 months after NAC initiation)
|
Proportion of patients achieving pCR after completion of neoadjuvant chemotherapy, defined as ypT0/is ypN0 (no invasive cancer in the breast and ipsilateral axillary lymph nodes; ductal carcinoma in situ may be present), consistent with RCB-0. |
At definitive surgery after completion of NAC (approximately 4-6 months after NAC initiation)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Residual Cancer Burden (RCB) Class
Lasso di tempo: At definitive surgery after completion of NAC (approximately 4-6 months after NAC initiation)
|
RCB class (RCB-0, RCB-I, RCB-II, RCB-III) quantifying residual tumor in the breast and lymph nodes after neoadjuvant therapy, calculated using the internationally validated MD Anderson Cancer Center RCB calculator based on standardized pathological assessment of surgical specimens. |
At definitive surgery after completion of NAC (approximately 4-6 months after NAC initiation)
|
|
Invasive Disease-Free Survival (iDFS)
Lasso di tempo: From enrollment until event or study end, assessed every 6 months (up to approximately 5 years)
|
Time from enrollment to the first occurrence of any of the following: ipsilateral invasive breast cancer recurrence, contralateral invasive breast cancer, distant metastasis, second primary non-breast invasive malignancy, or death from any cause (conservative definition including all deaths), per established consensus definitions. Follow-up includes clinical visits and imaging (breast ultrasound/MRI, chest-abdominal CT, bone scan as risk-stratified) every 6 months. |
From enrollment until event or study end, assessed every 6 months (up to approximately 5 years)
|
|
Progression-Free Survival (PFS)
Lasso di tempo: From enrollment until event or study end (up to approximately 5 years)
|
Time from enrollment to the first radiographically confirmed disease progression (per RECIST 1.1) or death from any cause. This outcome is only available for M1 patients. |
From enrollment until event or study end (up to approximately 5 years)
|
|
Overall Survival (OS)
Lasso di tempo: From enrollment until death or study end (up to approximately 5 years or longer)
|
Time from enrollment to death from any cause. Death events are confirmed by death certificates, hospital records, or national vital registration systems. Patients lost to follow-up are censored at the date of last contact. |
From enrollment until death or study end (up to approximately 5 years or longer)
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie intestinali
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Neoplasie intestinali
- Malattie del retto
- Malattie polmonari
- Malattie del fegato
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie del fegato
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie del colon
- Neoplasie polmonari
- Malattie della pelle
- Malattie del seno
- Carcinoma
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Malattie della pelle e del tessuto connettivo
- Neoplasie allo stomaco
- Carcinoma, epatocellulare
- Neoplasie colorettali
- Neoplasie mammarie
- Carcinoma, polmone non a piccole cellule
Altri numeri di identificazione dello studio
- 2026-SSKY-048
- 2026-SSKY-048 (Altro identificatore: Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data may be made available upon reasonable request to the corresponding investigator after publication of the primary results, subject to institutional and ethics committee approval.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .